ANTHOS THERAPEUTICS

Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular and metabolic diseases.

Read More

ANTHOS THERAPEUTICS

Accelerating the development of life-preserving therapies for patients at high-risk of cardiovascular and metabolic diseases.

Read More

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.

Our Science

Our most advanced program is abelacimab, an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI through dual activity against both Factor XI itself and its activated form, Factor XIa. Abelacimab represents a promising next-generation anticoagulant with the potential to provide ‘hemostasis-sparing anticoagulation’: vital protection from arterial and venous thromboembolic events with a reduced risk of clinically significant bleeding.

A Major Unmet Need

Due to prevailing fears of bleeding, effective prevention of thromboembolic events through optimal anticoagulation remains a real-world unmet need.

Read more

The Promise of Factor XI inhibition

Through targeting Factor XI, our vision is to pharmacologically ‘uncouple’ pathological thrombosis from physiological hemostasis, bringing the paradigm shift of ‘hemostasis-sparing’ anticoagulation within reach.

Read more

Watch: Factor XI inhibition—uncoupling hemostasis from thrombosis

About abelacimab

Abelacimab, with its novel dual activity against Factor XI and XIa, has the potential to turn our vision of hemostasis-sparing anticoagulation into reality.

Read more

About abelacimab

Our Team

Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular and metabolic disease.

Read more

Our Team

Anthos Therapeutics is led by a world-class executive team highly experienced in the successful development of therapies for cardiovascular and metabolic disease.

Read more

News

ABELACIMAB SIGNIFICANTLY OUTPERFORMS STANDARD OF CARE IN PHASE 2 EFFICACY RESEARCH

Data showed that a single postoperative dose of Anthos Therapeutics’ novel Factor XI inhibitor abelacimab, reduced the rate of venous thromboembolism by ~80% compared to enoxaparin, following elective total knee arthroplasty, the gold standard setting for potential new anticoagulants to demonstrate efficacy

virtual congress

Factor XI Inhibition: The Holy Grail of Hemostasis‐ Sparing Anticoagulation

Click here to view the Anthos Therapeutics satellite symposium, which took place during ISTH 2021 on 20th July 2021.

Live discussion and Q&A about anti-coagulation and Factor XI

Click here to view the webinar, which took place on the 22nd July 2021.
The webinar will be led by:
Dr. Dan Bloomfield, MD, FACC, FAHA, Anthos Therapeutics
Lord Ajay Kakkar, Thrombosis Research Institute, London
Dr. Jeffrey Weitz, McMaster University, Thrombosis and Atherosclerosis Research Institute